Boston Scientific and Intuitive Surgical are two of the most widely followed names in medical technology, yet they occupy very different corners of the sector. Comparing BSX and ISRG offers investors a useful lens on two distinct business models: a diversified device maker versus a focused robotics pioneer. This stock comparison is relevant for traders monitoring relative performance and market positioning, as well as longer-term investors weighing growth durability against valuation. Both companies have experienced notable sentiment shifts in recent weeks, making the contrast between their fundamentals and their share-price behavior particularly instructive in the current market environment.
Boston Scientific is a diversified medical-device company spanning cardiology, electrophysiology, urology, neuromodulation, and interventional oncology. Its portfolio includes the WATCHMAN left-atrial-appendage closure device and the FARAPULSE pulsed field ablation (PFA) system, a technology used to treat atrial fibrillation.
In recent market activity, BSX has faced mounting pressure. The company reported first-quarter revenue of roughly $5.2 billion, up 11.6% on a reported basis, with adjusted earnings per share (EPS) of $0.80. However, management lowered full-year 2026 guidance, citing slower-than-expected WATCHMAN volumes in the U.S., competitive share losses in electrophysiology, and weakness in urology. Analysts responded by trimming price targets. Over the trailing 12 months, the stock has declined substantially, and it now trades at a relatively modest forward price-to-earnings (P/E) multiple compared with its historical average. A multi-year restructuring program targeting approximately $500 million in annual savings and a pending acquisition of Penumbra are among the catalysts investors are watching.
Intuitive Surgical is the pioneer and market leader in robotic-assisted surgery, best known for its da Vinci surgical systems and the Ion endoluminal platform for minimally invasive lung procedures. Its business benefits from a recurring revenue stream, as instruments and accessories now account for the large majority of sales.
Fundamentally, ISRG has delivered strong results in recent quarters. First-quarter revenue rose 23% year over year to about $2.77 billion, while adjusted EPS climbed 38% to $2.50. Worldwide procedures grew roughly 17%, driven by accelerating adoption of the newer da Vinci 5 system, and management raised its full-year procedure growth outlook to 13.5%–15.5%. Despite this momentum, the stock has fallen sharply in 2026. Investors have weighed concerns including Chinese competition, pressure on bariatric procedures from GLP-1 (glucagon-like peptide-1) weight-loss drugs, and an elevated valuation. The result is a notable divergence between solid operating performance and weaker recent share-price behavior.
For traders looking to translate comparative analysis like this into actionable signals, Tickeron's Trending AI Robots page offers a curated view of algorithmic trading strategies. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, but only a select group earns a place in this featured section based on their fit for current market conditions. These bots span diverse trading styles, timeframes, and risk profiles, each with its own performance statistics and set of traded tickers—from short-term momentum strategies to longer-horizon trend-following systems. Because not every bot suits every market regime, the Trending section is designed to highlight those currently demonstrating the strongest relative performance. Explore the Trending AI Robots page to see which strategies are leading today.
The most fundamental contrast between BSX and ISRG lies in their business models. BSX operates a broad, diversified portfolio that grows partly through acquisitions, spreading risk across multiple therapeutic areas but also exposing the company to integration challenges and competitive share shifts. ISRG is more concentrated, deriving its strength from a dominant installed base and high-margin recurring instrument revenue, which supports consistency but leaves it sensitive to procedure-volume trends and valuation expectations.
On growth drivers, ISRG is currently expanding procedures at a double-digit pace and raising guidance, while BSX has trimmed its outlook amid franchise-specific headwinds. On risk, BSX faces EP competition and product-quality scrutiny, whereas ISRG contends with emerging rivals in China and the U.S. and a premium valuation. Sector exposure is similar—both are healthcare names—but market sentiment has diverged: BSX's decline reflects fundamental concerns, while ISRG's sell-off has occurred despite strong results, suggesting valuation-driven repricing.
Based on observable factors such as trend consistency, stability, and catalysts, Tickeron's AI would likely favor ISRG in the current environment. Intuitive Surgical's combination of accelerating procedure growth, raised guidance, expanding margins, and a recurring-revenue base points to more consistent underlying momentum. In contrast, BSX's reduced guidance and competitive pressures introduce greater near-term uncertainty, even though its lower valuation and restructuring plan could offer value to patient investors. This verdict reflects a probabilistic, data-driven read of relative positioning rather than a forecast of either stock's future price, and it could shift as new fundamentals and market conditions emerge.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Aroon Indicator for BSX entered a downward trend on October 13, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 136 similar instances where the Aroon Indicator formed such a pattern. In 91 of the 136 cases the stock moved lower. This puts the odds of a downward move at 67%.
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In 48 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
BSX moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BSX crossed bearishly below the 50-day moving average on September 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 47%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BSX's RSI Oscillator exited the oversold zone, 17 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 28 of 51 cases where BSX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 55%.
The Moving Average Convergence Divergence (MACD) for BSX just turned positive on October 12, 2026. Looking at past instances where BSX's MACD turned positive, the stock continued to rise in 22 of 45 cases over the following month. The odds of a continued upward trend are 49%.
Following a +4.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 200 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
BSX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.564) is normal, around the industry mean (10.930). P/E Ratio (17.858) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
ISRG moved above its 50-day moving average on September 14, 2026 date and that indicates a change from a downward trend to an upward trend. In 21 of 29 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 72%.
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ISRG as a result. In 56 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for ISRG just turned positive on September 14, 2026. Looking at past instances where ISRG's MACD turned positive, the stock continued to rise in 26 of 44 cases over the following month. The odds of a continued upward trend are 59%.
The 10-day moving average for ISRG crossed bullishly above the 50-day moving average on September 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 58%.
Following a +2.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 211 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 183 of 264 cases where ISRG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
The 10-day RSI Indicator for ISRG moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 11 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 30%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
ISRG broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ISRG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.065) is normal, around the industry mean (5.011). P/E Ratio (47.568) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (1.931) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.074).
The Tickeron Profit vs. Risk Rating rating for this company is 81 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock better than average.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
BSX | ISRG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 72 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 81 | |
SMR RATING 1..100 | 55 | 51 | |
PRICE GROWTH RATING 1..100 | 62 | 42 | |
P/E GROWTH RATING 1..100 | 98 | 66 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BSX's Valuation (65) in the Medical Specialties industry is in the same range as ISRG (76). This means that BSX’s stock grew similarly to ISRG’s over the last 12 months.
ISRG's Profit vs Risk Rating (81) in the Medical Specialties industry is in the same range as BSX (100). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is in the same range as BSX (55). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
ISRG's Price Growth Rating (42) in the Medical Specialties industry is in the same range as BSX (62). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
ISRG's P/E Growth Rating (66) in the Medical Specialties industry is in the same range as BSX (98). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
| BSX | ISRG | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 65% | 1 day ago 30% |
| Stochastic ODDS (%) | 1 day ago 55% | 1 day ago 59% |
| Momentum ODDS (%) | 1 day ago 53% | 1 day ago 71% |
| MACD ODDS (%) | 1 day ago 49% | 1 day ago 59% |
| TrendWeek ODDS (%) | 1 day ago 57% | 1 day ago 64% |
| TrendMonth ODDS (%) | 1 day ago 56% | 1 day ago 65% |
| Advances ODDS (%) | 3 days ago 59% | 3 days ago 66% |
| Declines ODDS (%) | 8 days ago 54% | 13 days ago 61% |
| BollingerBands ODDS (%) | 1 day ago 65% | 1 day ago 48% |
| Aroon ODDS (%) | 1 day ago 67% | 1 day ago 69% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BSX’s FA Score shows that 0 FA rating(s) are green while ISRG’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BSX’s TA Score shows that 5 TA indicator(s) are bullish while ISRG’s TA Score has 6 bullish TA indicator(s).
BSX (@Medical/Nursing Services) experienced а +2.65% price change this week, while ISRG (@Pharmaceuticals: Other) price change was +4.27% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.08%. For the same industry, the average monthly price growth was -4.01%, and the average quarterly price growth was -11.30%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.23%. For the same industry, the average monthly price growth was -3.14%, and the average quarterly price growth was +7.32%.
BSX is expected to report earnings on Oct 28, 2026.
ISRG is expected to report earnings on Oct 20, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (-1.23% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
A.I.dvisor indicates that over the last year, BSX has been closely correlated with ISRG. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BSX jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To BSX | 1D Price Change % | ||
|---|---|---|---|---|
| BSX | 100% | -1.21% | ||
| ISRG - BSX | 71% Closely correlated | -1.30% | ||
| MMSI - BSX | 56% Loosely correlated | -1.79% | ||
| ALC - BSX | 49% Loosely correlated | -2.10% | ||
| MDT - BSX | 46% Loosely correlated | +1.17% | ||
| NTRA - BSX | 45% Loosely correlated | -0.53% | ||
More | ||||
A.I.dvisor indicates that over the last year, ISRG has been closely correlated with BSX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ISRG jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To ISRG | 1D Price Change % | ||
|---|---|---|---|---|
| ISRG | 100% | -1.30% | ||
| BSX - ISRG | 73% Closely correlated | -1.21% | ||
| SYK - ISRG | 64% Loosely correlated | -0.02% | ||
| NTRA - ISRG | 54% Loosely correlated | -0.53% | ||
| GKOS - ISRG | 51% Loosely correlated | -1.50% | ||
| PODD - ISRG | 49% Loosely correlated | -1.20% | ||
More | ||||